Company Details
catalent
12,729
315,074
3254
catalent.com
0
CAT_4101033
In-progress


Catalent Company CyberSecurity Posture
catalent.comChampioning the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.
Company Details
catalent
12,729
315,074
3254
catalent.com
0
CAT_4101033
In-progress
Between 750 and 799

Catalent Global Score (TPRM)XXXX



No incidents recorded for Catalent in 2026.
No incidents recorded for Catalent in 2026.
No incidents recorded for Catalent in 2026.
Catalent cyber incidents detection timeline including parent company and subsidiaries

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.


Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrol

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldw

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient,
Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portf
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye ca

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy b
.png)
BMO and Catalent Pharma Solutions Partner with OpenText to Transform Business Operations and Drive Innovation. WATERLOO, ON, April 14,...

Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.
The official website of Catalent is https://www.catalent.com.
According to Rankiteo, Catalent’s AI-generated cybersecurity score is 781, reflecting their Fair security posture.
According to Rankiteo, Catalent currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.
According to Rankiteo, Catalent has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.
According to Rankiteo, Catalent is not certified under SOC 2 Type 1.
According to Rankiteo, Catalent does not hold a SOC 2 Type 2 certification.
According to Rankiteo, Catalent is not listed as GDPR compliant.
According to Rankiteo, Catalent does not currently maintain PCI DSS compliance.
According to Rankiteo, Catalent is not compliant with HIPAA regulations.
According to Rankiteo,Catalent is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.
Catalent operates primarily in the Pharmaceutical Manufacturing industry.
Catalent employs approximately 12,729 people worldwide.
Catalent presently has no subsidiaries across any sectors.
Catalent’s official LinkedIn profile has approximately 315,074 followers.
Catalent is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.
No, Catalent does not have a profile on Crunchbase.
Yes, Catalent maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/catalent.
As of January 23, 2026, Rankiteo reports that Catalent has not experienced any cybersecurity incidents.
Catalent has an estimated 5,507 peer or competitor companies worldwide.
Total Incidents: According to Rankiteo, Catalent has faced 0 incidents in the past.
Incident Types: The types of cybersecurity incidents that have occurred include .
.png)
Backstage is an open framework for building developer portals, and @backstage/backend-defaults provides the default implementations and setup for a standard Backstage backend app. Prior to versions 0.12.2, 0.13.2, 0.14.1, and 0.15.0, the `FetchUrlReader` component, used by the catalog and other plugins to fetch content from URLs, followed HTTP redirects automatically. This allowed an attacker who controls a host listed in `backend.reading.allow` to redirect requests to internal or sensitive URLs that are not on the allowlist, bypassing the URL allowlist security control. This is a Server-Side Request Forgery (SSRF) vulnerability that could allow access to internal resources, but it does not allow attackers to include additional request headers. This vulnerability is fixed in `@backstage/backend-defaults` version 0.12.2, 0.13.2, 0.14.1, and 0.15.0. Users should upgrade to this version or later. Some workarounds are available. Restrict `backend.reading.allow` to only trusted hosts that you control and that do not issue redirects, ensure allowed hosts do not have open redirect vulnerabilities, and/or use network-level controls to block access from Backstage to sensitive internal endpoints.
Backstage is an open framework for building developer portals, and @backstage/cli-common provides config loading functionality used by the backend and command line interface of Backstage. Prior to version 0.1.17, the `resolveSafeChildPath` utility function in `@backstage/backend-plugin-api`, which is used to prevent path traversal attacks, failed to properly validate symlink chains and dangling symlinks. An attacker could bypass the path validation via symlink chains (creating `link1 → link2 → /outside` where intermediate symlinks eventually resolve outside the allowed directory) and dangling symlinks (creating symlinks pointing to non-existent paths outside the base directory, which would later be created during file operations). This function is used by Scaffolder actions and other backend components to ensure file operations stay within designated directories. This vulnerability is fixed in `@backstage/backend-plugin-api` version 0.1.17. Users should upgrade to this version or later. Some workarounds are available. Run Backstage in a containerized environment with limited filesystem access and/or restrict template creation to trusted users.
Backstage is an open framework for building developer portals. Multiple Scaffolder actions and archive extraction utilities were vulnerable to symlink-based path traversal attacks. An attacker with access to create and execute Scaffolder templates could exploit symlinks to read arbitrary files via the `debug:log` action by creating a symlink pointing to sensitive files (e.g., `/etc/passwd`, configuration files, secrets); delete arbitrary files via the `fs:delete` action by creating symlinks pointing outside the workspace, and write files outside the workspace via archive extraction (tar/zip) containing malicious symlinks. This affects any Backstage deployment where users can create or execute Scaffolder templates. This vulnerability is fixed in `@backstage/backend-defaults` versions 0.12.2, 0.13.2, 0.14.1, and 0.15.0; `@backstage/plugin-scaffolder-backend` versions 2.2.2, 3.0.2, and 3.1.1; and `@backstage/plugin-scaffolder-node` versions 0.11.2 and 0.12.3. Users should upgrade to these versions or later. Some workarounds are available. Follow the recommendation in the Backstage Threat Model to limit access to creating and updating templates, restrict who can create and execute Scaffolder templates using the permissions framework, audit existing templates for symlink usage, and/or run Backstage in a containerized environment with limited filesystem access.
FastAPI Api Key provides a backend-agnostic library that provides an API key system. Version 1.1.0 has a timing side-channel vulnerability in verify_key(). The method applied a random delay only on verification failures, allowing an attacker to statistically distinguish valid from invalid API keys by measuring response latencies. With enough repeated requests, an adversary could infer whether a key_id corresponds to a valid key, potentially accelerating brute-force or enumeration attacks. All users relying on verify_key() for API key authentication prior to the fix are affected. Users should upgrade to version 1.1.0 to receive a patch. The patch applies a uniform random delay (min_delay to max_delay) to all responses regardless of outcome, eliminating the timing correlation. Some workarounds are available. Add an application-level fixed delay or random jitter to all authentication responses (success and failure) before the fix is applied and/or use rate limiting to reduce the feasibility of statistical timing attacks.
The Flux Operator is a Kubernetes CRD controller that manages the lifecycle of CNCF Flux CD and the ControlPlane enterprise distribution. Starting in version 0.36.0 and prior to version 0.40.0, a privilege escalation vulnerability exists in the Flux Operator Web UI authentication code that allows an attacker to bypass Kubernetes RBAC impersonation and execute API requests with the operator's service account privileges. In order to be vulnerable, cluster admins must configure the Flux Operator with an OIDC provider that issues tokens lacking the expected claims (e.g., `email`, `groups`), or configure custom CEL expressions that can evaluate to empty values. After OIDC token claims are processed through CEL expressions, there is no validation that the resulting `username` and `groups` values are non-empty. When both values are empty, the Kubernetes client-go library does not add impersonation headers to API requests, causing them to be executed with the flux-operator service account's credentials instead of the authenticated user's limited permissions. This can result in privilege escalation, data exposure, and/or information disclosure. Version 0.40.0 patches the issue.

Get company history
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.
Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.
Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.
Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.